What's Happening?
Japanese contract development and manufacturing organization (CDMO) Peptistar has begun operating Asahi Kasei's forward osmosis-membrane distillation (FO-MD) system at a manufacturing scale. This system, developed by Asahi Kasei, allows for the dehydration
and concentration of liquids without heat or pressure, reducing the time and cost associated with traditional freeze-drying methods. The integration of this system is part of Peptistar's efforts to streamline the production of active pharmaceutical ingredients (APIs), particularly those that are heat-sensitive, such as peptides and oligonucleotides. The FO-MD system addresses challenges in API manufacturing by concentrating raw materials under mild conditions, thus preserving quality and reducing energy consumption.
Why It's Important?
The adoption of the FO-MD system by Peptistar represents a significant advancement in the manufacturing of APIs, particularly for next-generation therapeutics that require precise and gentle processing. This technology could lead to more efficient production processes, reducing costs and time-to-market for new drugs. As the demand for complex APIs grows, innovations like the FO-MD system are crucial for meeting industry needs while maintaining high-quality standards. This development highlights the ongoing evolution in pharmaceutical manufacturing, where companies are increasingly adopting advanced technologies to enhance production capabilities and competitiveness.
What's Next?
Peptistar's implementation of the FO-MD system is currently at the trial production stage, with evaluations ongoing for potential GMP production. As the company assesses the system's performance, there may be further developments in its application across other manufacturing processes. The success of this technology could encourage broader adoption within the pharmaceutical industry, particularly for the production of heat-sensitive APIs. Asahi Kasei is also exploring the commercialization prospects of the FO-MD system, which could lead to its wider availability and use in pharmaceutical manufacturing globally.
